Shuchi Nahar's Weekend Blog!

Syngene International Ltd. FY2020-21 Annual Report Key Takeaways  In continuation of my previous blog here is the updated version l ink to Initial Blog -  https://myweekendspot.blogspot.com/2020/10/syngene-next-giant-player-for-cdmo.html Company Overview Incorporated in 1994 as a subsidiary of Biocon, Syngene International (SIL) is a leading contract research organization (CRO), which supports R&D programs of global innovative companies.   SIL offers outsourced services to support discovery and development for organizations across industrial sectors like pharmaceuticals, biopharmaceuticals, nutraceuticals, animal health, agrochemicals, etc. It currently caters to 400+ global players including Bristol-Myers Squibb (BMS), Abbott, Baxter, and Amgen, among others. SIL derives 95% of its revenues from exports.   Syngene continued to build on its integrated drug discovery and development portfolio during the year, including a five-year collaboration with 3DC, the drug discovery

Laurus Labs - Result Update Q4FY21 & Full Year FY21 Twitter Handle: @shuchi_nahar Laurus Labs Limited on 30th April 2021 announced its Q4FY21 and full-year results.  Laurus Lab performed extremely well consecutive in the 4th Quarter of FY21. The company did a robust growth in all three segments. Having a healthy order book for FY 22. Consolidated revenue for the quarter increased by 70% driven by growth in all the divisions. The company has been able to sustain its EBITDA margins, and profitability has also improved to Rs. 297 Crs. for the quarter. Generic API division showcased a robust growth of 61% YoY. Anti Viral segment recorded a robust growth of 70% YoY. Revenue Showcased a healthy growth of 102% YoY. The growth was led by higher LMIC Market volumes and increased volumes from North America and EU Commenced marketing of in-licensed products in the USA to leverage front-end capabilities. Custom Synthesis division recorded a strong growth of 35% YoY. Capacity Expansion – To

Syngene Q4FY21 and Full Year FY21 - Result Update  Twitter Handle: @shuchi_nahar Syngene International Limited on 28 th April 2021 announced its Q4FY21 and full-year results. The Company reported quarterly revenue from operations of Rs. 659 Cr and Rs. 2,184 Cr for the full year. Underlying revenue from operations (excluding export incentives) for the quarter grew 13% compared with the same period last year and by 12% for the full year. Profit after tax (before exceptional gain) for the quarter increased by 15% year-on-year to Rs. 138 Cr, and by 4% to Rs. 382 Cr for the full year. Revenue Growth over the Years 1. Growth driven by an increase in sales from existing clients and acquisition of new clients  2. Engage, expand and extend the strategy to extend client relationship over a longer period of time  3. Growth in the total number of clients  4. Increase in average revenue from largest clients  5. Increase in number of services offered to clients The highlight of the quarter was the

Neogen Chemical Ltd - Company Overview & Indian Chemical Industry S ynopsis T witter Handle: @shuchi_nahar Company Overview India’s one of the largest manufacturers of Bromine-based compounds, Inorganic Lithium Salts, which mainly find applications in Pharmaceutical, Agrochemical, Specialty Polymer, Heating, Ventilation and Air Conditioning (HVAC) and Flavors and Fragrance Chemicals. Operating since 1991 with strong portfolio of Organic and Inorganic products.  Customers across multiple industries including Pharma, Engineering, and Agrochem Key export geographies include the USA, Europe, Japan and Middle East Growing contribution from Custom Synthesis and Contract Manufacturing Executing Brownfield manufacturing capacity expansion Promoters are pioneering technocrats with substantial domain expertise cumulative experience of more than six decades Developed strong R&D capabilities with dedicated in-house team. Source: Neogen Chemical AnnualReport & Investor Presentation Comp

  Your ultimate guide to understand the basics and details about the Indian Pharma Sector A Brief Understanding On Pharma Sector From Its Key Terms To Its Filing And Procedures. The following article is on the Indian Pharmaceutical Industry, the article is written to familiarize ourselves with the terminology or the jargon’s of the pharmaceutical industry. It will briefly touch upon terms like API, Intermediates, CDMO’s/ CRAM’s, PARA Filings,  Innovator drug, Generic drugs, life cycle development etc. The Indian pharmaceuticals market has characteristics that make it unique. First, branded generics dominate, making up for 70 to 80% of the retail market.  India also has the feather of being the  largest exporter of generic drugs  in the world.  Second, local players have enjoyed a dominant position driven by the formulation development capabilities and early investments.  Third, price levels are low, driven by intense competition. While India ranks tenth globally in terms of value, it

  Laurus Labs Ltd. –Story of Patience, diligence, and perseverance Twitter Handle: @shuchi_nahar Link to Company Overview of Laurus Labs in detail: https://myweekendspot.blogspot.com/2020/09/laurus-labs-company-overview.html Result Update – Q3FY21 Laurus Lab performed extremely well consecutive in the 3 rd  quarter of FY21. The company did a robust growth in all three segments. Having   a healthy order book for FY 21 & beyond in FDF CMO business with a strategic partner in EU. Consolidated revenue for the quarter increased by 76% driven by growth in all the divisions. The company has been able to sustain its EBITDA margins, and profitability has also improved to Rs. 273 Crs. for the quarter. The generic API division recorded a healthy growth of over 100% for the quarter, the growth was led by higher growth in ARV API business in turn led by higher volume of 1st line products. The Formulations business showcased a growth of over 120% for the 9M period, led by higher LMIC bus